{"id":3756,"date":"2018-12-11T15:15:20","date_gmt":"2018-12-11T09:45:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3756"},"modified":"2021-07-24T12:57:09","modified_gmt":"2021-07-24T07:27:09","slug":"notizia-83","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-83","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Axovant tips nelotanserin from small molecule R&amp;D<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Axovant<\/strong> has\u00a0stopped <strong>nelotanserin<\/strong> development after it missed the primary endpoint in a <strong>phase 2 trial<\/strong> in patients with <strong>Lewy body <a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-market\">dementia<\/a><\/strong>. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent company of Axovant \u2013 Roivant, licensed <strong>5HT2A<\/strong> inverse serotonin receptor agonist nelotanserin from <strong>Arena Pharmaceuticals<\/strong> for USD 4 million upfront in 2015 and initiated midphase trials of the drug in patients with dementia with Lewy bodies (DLB) and <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">Parkinson\u2019s<\/a> disease dementia.<\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR-based heart test identifies genetic risk for severe cardiomyopathy<\/strong><\/p>\n<p style=\"text-align: justify;\">A dangerous disorder that causes an abnormal thickening of the heart walls &#8211; Severe hypertrophic <a href=\"https:\/\/www.delveinsight.com\/report-store\/dilated-cardiomyopathy-pipeline-insight\">cardiomyopathy<\/a> can be found in hereditary and is often associated with a variant in the <strong>gene TNNT2<\/strong>. The scientists at the <strong>University of Pennsylvania<\/strong> has developed a test with <strong>CRISPR<\/strong> and other gene-editing tools that they believe can be used to screen for potentially harmful variations of TNNT2. They developed the test with the help of one family affected by severe hypertrophic cardiomyopathy. That is why they used gene editing to create induced <strong>pluripotent stem cells (iPSCs)<\/strong> containing the woman\u2019s TNNT2 variant, which then prompted the iPSCs to turn into mature heart muscle cells and exposed them to an adrenaline-like chemical to induce faster beating.<\/p>\n<p style=\"text-align: justify;\"><strong>MacroGenics stops cancer drug trials <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>MacroGenics<\/strong> developed the bispecific antibody for potential liver-related side effects that led to the <strong>FDA<\/strong> placing a partial clinical hold. Maryland-based MacroGenics, a letter was sent regarding placing the hold on a<strong> phase 1 trial<\/strong> of <strong>MGD009<\/strong> as a monotherapy as well as a combination study with <strong>Incyte\u2019s anti-PD-1 candidate MGA012<\/strong>. MacroGenics\u00a0claims\u00a0the development is not a big hindrance, directing at the block only applies to recruit new subjects, and existing patients in both studies can continue on treatment under the assigned protocol.<\/p>\n<p style=\"text-align: justify;\"><strong>Novo taps e-therapeutics for diabetes target discovery drive<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Novo Nordisk<\/strong> has listed e-therapeutics to bolster target discovery efforts at its research centre in <strong>Oxford<\/strong>, U.K. The\u00a0collaboration\u00a0will get to see e-therapeutics apply its platform to identify synergistic target combinations to a specific area of <strong>Type 2 diabetes<\/strong>. E-therapeutics analyzes biological networks. Instead of searching for single targets that change disease pathways, e-therapeutics creates in-silico networks of protein interactions and looks for ways to disrupt the system that gives rise to the disease phenotype. This can yield multitarget strategies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Axovant tips nelotanserin from small molecule R&amp;D Axovant has\u00a0stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent company of Axovant \u2013 Roivant, licensed [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3649,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2299,2296,647,704,2301,2298,2304,2297,877,2305,2303,2300,2023,2302],"industry":[17225],"therapeutic_areas":[17242,17240,17245],"class_list":["post-3756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-arena-pharmaceuticals","tag-axovant","tag-crispr","tag-fda","tag-gene-tnnt2","tag-lewy-body-dementia","tag-macrogenics","tag-nelotanserin","tag-novo-nordisk","tag-oxford","tag-pluripotent-stem-cells-ipscs","tag-severe-hypertrophic-cardiomyopathy","tag-type-2-diabetes","tag-university-of-pennsylvania","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 11\/12\/2018 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Axovant has\u00a0stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-83\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 11\/12\/2018 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Axovant has\u00a0stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-83\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-11T09:45:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"752\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 11\/12\/2018 - DelveInsight Business Research","description":"Axovant has\u00a0stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-83","og_locale":"en_US","og_type":"article","og_title":"Notizia 11\/12\/2018 - DelveInsight Business Research","og_description":"Axovant has\u00a0stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia..","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-83","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-12-11T09:45:20+00:00","article_modified_time":"2021-07-24T07:27:09+00:00","og_image":[{"width":752,"height":501,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-83","url":"https:\/\/www.delveinsight.com\/blog\/notizia-83","name":"Notizia 11\/12\/2018 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-83#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-83#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","datePublished":"2018-12-11T09:45:20+00:00","dateModified":"2021-07-24T07:27:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Axovant has\u00a0stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-83"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-83#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","width":752,"height":501,"caption":"patent ductus arteriosus"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arena Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Axovant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">gene TNNT2<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lewy body dementia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MacroGenics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">nelotanserin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oxford<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pluripotent stem cells (iPSCs)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Severe hypertrophic cardiomyopathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Type 2 diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">University of Pennsylvania<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Arena Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Axovant<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">gene TNNT2<\/span>","<span class=\"advgb-post-tax-term\">Lewy body dementia<\/span>","<span class=\"advgb-post-tax-term\">MacroGenics<\/span>","<span class=\"advgb-post-tax-term\">nelotanserin<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Oxford<\/span>","<span class=\"advgb-post-tax-term\">pluripotent stem cells (iPSCs)<\/span>","<span class=\"advgb-post-tax-term\">Severe hypertrophic cardiomyopathy<\/span>","<span class=\"advgb-post-tax-term\">Type 2 diabetes<\/span>","<span class=\"advgb-post-tax-term\">University of Pennsylvania<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 11, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 11, 2018 3:15 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"patent ductus arteriosus","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3756"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3756\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3649"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3756"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3756"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}